NEO CR KNEE SYSTEM

K120313 · Pipeline Orthopedics · JWH · Apr 20, 2012 · Orthopedic

Device Facts

Record IDK120313
Device NameNEO CR KNEE SYSTEM
ApplicantPipeline Orthopedics
Product CodeJWH · Orthopedic
Decision DateApr 20, 2012
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Neo CR Knee System components are indicated for use in skeletally mature individuals, with severe knee pain and disability, with an intact posterior cruciate ligament, undergoing surgery for total knee replacement due to: - Osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, moderate deformities and femoral condyle osteonecrosis. - Failed osteotomies, failed partial knee replacement, or failed total knee replacement whose age, weight and activity level are compatible with an adequate long-term result. - Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy. - Moderate valgus, varus, or flexion deformities. NEO CR Knee System components are indicated for use only with cement and are single use devices.

Device Story

Total knee replacement system comprising femoral components, tibial trays, patellar components, and surgical instrumentation. Designed for high-flexion (up to 150 degrees) in patients with intact posterior cruciate ligament. Used by orthopedic surgeons in clinical/OR settings. Components implanted via cement fixation to replace damaged joint surfaces; restores joint configuration and function; alleviates pain and disability. Bench testing confirms mechanical integrity under physiological conditions.

Clinical Evidence

Bench testing only. Evaluations included tibial tray fatigue strength, insert locking mechanism strength, femorotibial range of motion, femorotibial/patellofemoral range of constraint, and contact area/stress analysis.

Technological Characteristics

Components manufactured from metals and UHMWPE compliant with implantable materials standards. Semi-constrained cemented prosthesis. Design features support high-flexion (150 degrees).

Indications for Use

Indicated for skeletally mature patients with severe knee pain/disability and intact posterior cruciate ligament requiring total knee replacement due to osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, moderate deformities, femoral condyle osteonecrosis, failed prior knee surgeries, or post-traumatic joint loss. For use only with cement; single use.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K 12.0313 (1/2) APR 2 0 2012 # NEO CR Knee System 510(k) Summary NEO CR Knee System Device Proprietary Name: Total Knee System Common Name: 888.3560 Classification regulation: Device Class: Class II Product Codes: JWH (cemented knees) Submitter's Name: Pipeline Orthopedics 3 Wing Drive, Suite 200, Cedar Knolls, NJ 07927 Address: Robert C. Cohen Contact Person: Telephone Number: (973) 267-8800 (973) 267-8810 Fax Number: April 17, 2012 Date Summary Prepared: #### Device Description: The NEO CR Knee System includes components designed for total knee replacement. The system includes femoral components, tibial trays, patellar components and surgical instrumentation. The Neo CR Knee System femoral component, when used with the Neo CR articular surfaces, is designed to achieve flexion at high angles and provide a clinical ROM up to 150 degrees. #### Intended Use The Neo CR Knee System components are indicated for use in skeletally mature individuals, with severe knee pain and disability, with an intact posterior cruciate ligament, undergoing surgery for total knee replacement due to: - Osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, moderate . deformities and femoral condyle osteonecrosis. - Failed osteotomies, failed partial knee replacement, or failed total knee . replacement whose age, weight and activity level are compatible with an adequate long-term result. - Post-traumatic loss of joint configuration, particularly when there is . patellofemoral erosion, dysfunction or prior patellectomy. - Moderate valgus, varus, or flexion deformities. . NEO CR Knee System components are indicated for use only with cement and are single use devices. {1}------------------------------------------------ ### NEO CR Knee System 510(k) Summary #### Predicate Devices: The NEO CR Knee System is similar to several predicates including the following. | Trade/Proprietary Name | Manufacturer | 510(K) # | Clearance<br>Date | |-------------------------------------------------------------------------------------|--------------|----------|-------------------| | NexGen Complete Knee Solution<br>Cruciate Retaining (CR)-Flex Femoral<br>Components | Zimmer | K023211 | 10/17/2002 | | Gender Solutions Natural-Knee Flex<br>System | Zimmer | K073286 | 03/07/2008 | | Triathlon Cruciate Retaining (Cr) Total<br>Knee System | Stryker | K040267 | 5/5/2004 | #### Technological Characteristics: The metals and standard UHMWPE material from which the components are manufactured are the same materials used in the predicate knee systems and comply with applicable implantable materials standards. A comparison of design features of the NEO CR Knee System to the predicate knee systems and performance testing confirm that the NEO CR Knee System is capable of withstanding the anticipated physiological conditions associated with the indications for use and is substantially equivalent to the predicate devices. #### Performance Testing: The NEO Knee System has been evaluated for tibial tray fatigue strength, insert locking mechanism strength, femorotibial range of motion, femorotibial range of constraint, patellofemoral range of constraint, femorotibial contact areas/contact stress, and patellofemoral contact area and contact stress. #### Substantial Equivalence Information: The NEO CR Knee System is similar to legally marketed devices listed previously in that they share similar indications for use and incorporate similar technological characteristics. All evaluations determined that the NEO CR Knee System is substantially equivalent to the predicate devices. {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight. # DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Pipeline Orthopedics, Incorporated % M Squared Associates Ms. Terry Sheridan Powell Consultant 901 King Street, Suite 200 Alexandria, Virginia 22314 Received: February 1, 2012 Re: K120313 Trade/Device Name: NEO CR Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prothesis Regulatory Class: Class II Product Code: JWH Dated: January 30, 2012 Dear Ms. Powell: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act that I Dr man matures and regulations administered by other Federal agencies. You must or any I vith all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set APR 2 0 2012 {3}------------------------------------------------ ### Page 2 - Ms. Terry Sheridan Powell forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFD/VCentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, for Datha Mrs. Linda Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indications for Use Statement 510(k) Number: To be assigned K120313 NEO CR Knee System Device Name: The NEO CR Knee System components are indicated for use in Indications for Use: skeletally mature individuals, with severe knee pain and disability, with an intact posterior cruciate ligament, undergoing surgery for total knee replacement due to: - Osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, moderate . deformities and femoral condyle osteonecrosis. - Failed osteotomies, failed partial knee replacement, or failed total knee . replacement whose age, weight and activity level are compatible with an adequate long-term result. - Post-traumatic loss of joint configuration, particularly when there is . patellofemoral erosion, dysfunction or prior patellectomy. - Moderate valgus, varus, or flexion deformities. . Neo CR Knee System components are indicated for use only with cement and are single use devices. Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) · Concurrence of CDRH, Office of Device Evaluation (ODE) Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number: K120313 Page 1 of ____________________________________________________________________________________________________________________________________________________________________
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%